title: Cardiovascular medication use following percutaneous coronary intervention: the Australian experience.
abstract: OBJECTIVE
  Despite the guidelines, a "treatment gap" exists in the delivery of pharmacotherapy for secondary prevention. We aimed to analyze the trend in guideline-based medication usage following percutaneous coronary intervention (PCI) using the Melbourne Interventional Group (MIG) registry over a 6-year period (2005-2010).
  
  
  METHODS
  The MIG registry prospectively collects demographical, clinical, and procedural characteristics of consecutive patients undergoing PCI. We assessed medication use (aspirin, clopidogrel, ACE inhibitors, angiotensin receptor blockers, beta-blockers, and lipid-lowering agents) at 30 days and 12 months in patients alive and able to provide the information.
  
  
  RESULTS
  The cohort consists of 12,813 patients who underwent 14,787 consecutive interventional procedures. They comprised 76% males: 22% were elderly (≥75 years), 23% had diabetes, 2% had severe renal impairment, 2% had severe left ventricular dysfunction, 26% presented with STEMI, and 44% of patients received drug-eluting stent. Follow-up was complete for 97.8% of the cohort at 30 days (2.2% mortality) and 89.1% at 12 months (4% mortality). From 2005 to 2010, the percentage of patients taking all five classes of medications increased each year. In 2010 at 30 days, nearly 60% of patients took all five classes of medications, and by 12 months, 75% of patients were taking four or five classes of medications.
  
  
  CONCLUSIONS
  In conclusion, while the increasing use of cardiovascular medicines in an "at-risk" Australian cohort is encouraging, a treatment gap appears to still exist.
authors.affiliation: Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Vic., Australia; Alfred Hospital, Melbourne, Vic., Australia.
authors.forename: Justin A
authors.initials: JA
authors.lastname: Cole
authors.forename: Angela L
authors.initials: AL
authors.lastname: Brennan
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Ajani
authors.forename: Bryan P
authors.initials: BP
authors.lastname: Yan
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Duffy
authors.forename: Philippa
authors.initials: P
authors.lastname: Loane
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Reid
authors.forename: Matias B
authors.initials: MB
authors.lastname: Yudi
authors.forename: Gishel
authors.initials: G
authors.lastname: New
authors.forename: Alexander
authors.initials: A
authors.lastname: Black
authors.forename: James
authors.initials: J
authors.lastname: Shaw
authors.forename: David J
authors.initials: DJ
authors.lastname: Clark
authors.forename: Nick
authors.initials: N
authors.lastname: Andrianopoulos
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000145:classification / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D017723:Drug Utilization Review; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000379:methods; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends; D011446:Prospective Studies; D012042:Registries; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods* / Q000639:trends; D013997:Time Factors; D016896:Treatment Outcome; D014739:Victoria
chemical_list: D002317:Cardiovascular Agents
keywords: Guidelines; Medications; Percutaneous coronary intervention; Registry